{"log_id": 5469596151737335134, "direction": 0, "words_result_num": 74, "words_result": [{"probability": {"variance": 2.4e-05, "average": 0.99254, "min": 0.987597}, "location": {"width": 29, "top": 48, "height": 20, "left": 83}, "words": "其它"}, {"probability": {"variance": 0.001157, "average": 0.988812, "min": 0.82876}, "location": {"width": 983, "top": 63, "height": 19, "left": 105}, "words": "与血管紧张素转换酶抑制剂相类似,本品与其它血管紧张素拮抗剂的降压效果在黑人低于对其它人种的疗效,这可能与黑人高血压人群的低肾素状态占较高优势有关"}, {"probability": {"variance": 8e-06, "average": 0.998482, "min": 0.982507}, "location": {"width": 682, "top": 83, "height": 17, "left": 105}, "words": "与其它抗高血压药物一样,对于患有缺血性心脏病或缺血性心血管疾病的患者,过度降压可以引起心肌梗塞或中风"}, {"probability": {"variance": 2e-06, "average": 0.998933, "min": 0.99554}, "location": {"width": 151, "top": 101, "height": 18, "left": 83}, "words": "对驾驶和操作机器的影响"}, {"probability": {"variance": 0.001969, "average": 0.987996, "min": 0.764727}, "location": {"width": 669, "top": 116, "height": 17, "left": 111}, "words": "未研究本品对驾驶和操作机器的影响。但是在驾驶或操作机器时必须注意,抗高血压治疗有时会引起头晕和瞌睡"}, {"probability": {"variance": 4e-06, "average": 0.997321, "min": 0.99355}, "location": {"width": 71, "top": 134, "height": 17, "left": 83}, "words": "糖尿病患者"}, {"probability": {"variance": 0.001982, "average": 0.991417, "min": 0.606187}, "location": {"width": 1055, "top": 147, "height": 20, "left": 111}, "words": "糖尿病伴有额外心血管危险因素的患者,如糖尿病伴冠状动脉疾病(CAD)的患者,使用血管紧张素受体拮抗剂或ACE抑制剂等降压药,可能增加致死性心肌梗死和心血管疾病意"}, {"probability": {"variance": 1.3e-05, "average": 0.997885, "min": 0.987071}, "location": {"width": 156, "top": 185, "height": 15, "left": 81}, "words": "【孕妇及哺乳期妇女用药】"}, {"probability": {"variance": 3.8e-05, "average": 0.995951, "min": 0.983659}, "location": {"width": 68, "top": 201, "height": 17, "left": 84}, "words": "妊娠期使用"}, {"probability": {"variance": 0.000481, "average": 0.991405, "min": 0.890347}, "location": {"width": 1054, "top": 216, "height": 18, "left": 111}, "words": "尚无足够数据显示本品能否用于妊娠妇女。动物试验未显示致畸性,但显示胚胎毒性。因此,慎重起见,在妊娠前三个月不要使用替米沙坦。在计划妊娠之前,应采取适宜的替"}, {"probability": {"variance": 1e-06, "average": 0.999113, "min": 0.997885}, "location": {"width": 41, "top": 236, "height": 15, "left": 85}, "words": "代疗法"}, {"probability": {"variance": 0.00109, "average": 0.990478, "min": 0.725798}, "location": {"width": 1053, "top": 249, "height": 19, "left": 111}, "words": "在妊娠的中末期(第二及第三个月期间),直接作用于肾素一血管紧张素系统的药物可导致胎儿的损伤甚至死亡,因此替米沙坦禁用于妊娠中末期。一旦确诊妊娠,应尽快停用本品"}, {"probability": {"variance": 0.000177, "average": 0.994141, "min": 0.937168}, "location": {"width": 438, "top": 267, "height": 19, "left": 83}, "words": "哺乳期使用由于本品是否经乳汁排出尚不得而知,故哺乳期间禁用本品"}, {"probability": {"variance": 6.4e-05, "average": 0.996534, "min": 0.956058}, "location": {"width": 496, "top": 288, "height": 18, "left": 80}, "words": "【儿童用药】对于儿童和18岁以下的青少年,本品的安全性及有效性数据尚未建立"}, {"probability": {"variance": 2e-06, "average": 0.998848, "min": 0.995423}, "location": {"width": 222, "top": 308, "height": 16, "left": 80}, "words": "【老年用药】服用本品不需调整剂量"}, {"probability": {"variance": 1.7e-05, "average": 0.997139, "min": 0.986843}, "location": {"width": 102, "top": 328, "height": 15, "left": 80}, "words": "【药物相互作用】"}, {"probability": {"variance": 0.003347, "average": 0.980965, "min": 0.586634}, "location": {"width": 1071, "top": 342, "height": 18, "left": 94}, "words": "1、锂剂:锂剂与血管紧张素转换酶抑制剂合用,可引起可逆性的血锂水平升高和毒性反应。也有个别病例是锂剂与血管紧张素Ⅱ受体拮抗剂合用引起的。因此,锂剂和本品合用须慎"}, {"probability": {"variance": 0.004838, "average": 0.977642, "min": 0.685698}, "location": {"width": 259, "top": 361, "height": 16, "left": 83}, "words": "重。如需合用,则合用期间应监测血锂水平"}, {"probability": {"variance": 0.002284, "average": 0.988253, "min": 0.637483}, "location": {"width": 778, "top": 393, "height": 18, "left": 83}, "words": "议监测血钾水平。基于使用其它影响肾素一血管紧张素系统药物的经验,本品与上述药物合用,可致血钾水平升高(参见注意事项)"}, {"probability": {"variance": 0.005843, "average": 0.973829, "min": 0.529345}, "location": {"width": 1070, "top": 409, "height": 18, "left": 96}, "words": "3、药代动力学试验已经研究了本品与地高辛、华法林、氢氯噻嗪、格列苯脲、布洛芬、扑热息痛、氨氧地平等药物的相互作用。可升高地高辛平均波谷血药浓度20%(个别病例升高"}, {"probability": {"variance": 0.001489, "average": 0.985682, "min": 0.841414}, "location": {"width": 212, "top": 428, "height": 15, "left": 83}, "words": "39%),因此须监测地高辛血浆浓度"}, {"probability": {"variance": 0.00841, "average": 0.982018, "min": 0.420596}, "location": {"width": 529, "top": 444, "height": 16, "left": 96}, "words": "4本品可加强其它抗高血压药物的降压效果。其它临床上有意义的相互作用尚不能证实"}, {"probability": {"variance": 0.001348, "average": 0.988562, "min": 0.751407}, "location": {"width": 597, "top": 477, "height": 17, "left": 96}, "words": "6、当与替米沙坦合用时,辛伐他汀代谢物(辛伐他汀酸)的Cmax有轻度升高(1.34倍)且消除加速"}, {"probability": {"variance": 1e-06, "average": 0.998681, "min": 0.997244}, "location": {"width": 76, "top": 496, "height": 15, "left": 80}, "words": "【药物过量】"}, {"probability": {"variance": 0.003353, "average": 0.98334, "min": 0.595156}, "location": {"width": 1054, "top": 510, "height": 18, "left": 111}, "words": "尚无过量使用的病例报告:替米沙坦过量最可能的表现是低血压和心动过速:心动过缓也可能发生。替米沙坦不能经血液透析消除。一旦发生过量,应对患者做密切观察,并做"}, {"probability": {"variance": 0.006519, "average": 0.975476, "min": 0.545096}, "location": {"width": 1082, "top": 527, "height": 18, "left": 84}, "words": "对症和支持治疗。治疗应根据服药的时间和症状的严重性。推荐的措施包括催吐和/或洗胃,活性炭治疗过量可能有效。应密切监测血电解质和肌酐。若发生低血压,患者应平卧,并"}, {"probability": {"variance": 1.7e-05, "average": 0.996243, "min": 0.989175}, "location": {"width": 124, "top": 545, "height": 16, "left": 84}, "words": "尽快补充盐分和扩容"}, {"probability": {"variance": 6.6e-05, "average": 0.992166, "min": 0.977735}, "location": {"width": 74, "top": 564, "height": 15, "left": 82}, "words": "【药理毒理】"}, {"probability": {"variance": 0, "average": 0.999262, "min": 0.99847}, "location": {"width": 55, "top": 580, "height": 16, "left": 85}, "words": "药理作用"}, {"probability": {"variance": 0.000193, "average": 0.992455, "min": 0.941601}, "location": {"width": 332, "top": 648, "height": 15, "left": 86}, "words": "AT2和其它特征更少的AT受体,功能尚不清楚)无亲和力"}, {"probability": {"variance": 0.00552, "average": 0.976986, "min": 0.616705}, "location": {"width": 697, "top": 663, "height": 17, "left": 112}, "words": "在人体,给予80mg替米沙坦几乎可完全抑制血管紧张素II引起的血压升高,抑制效应持续24小时,在48小时仍可测到"}, {"probability": {"variance": 0.002182, "average": 0.99158, "min": 0.671925}, "location": {"width": 642, "top": 680, "height": 17, "left": 112}, "words": "首剂替米沙坦后3小时内降压效应逐渐明显。在治疗开始后4周可获得最大降压效果,并可在长期治疗中维持"}, {"probability": {"variance": 0.000892, "average": 0.990418, "min": 0.772093}, "location": {"width": 1054, "top": 696, "height": 18, "left": 112}, "words": "动态血压监测显示,服药后降压效果持续超过24小时,包括下次给药前的4小时。这一结果在安慰剂对照的临床实验研究中得到证实:服用替米沙坦40mg和80mg后波谷与波峰的比"}, {"probability": {"variance": 0.000128, "average": 0.993827, "min": 0.962392}, "location": {"width": 117, "top": 715, "height": 15, "left": 85}, "words": "值持续地在80%以上"}, {"probability": {"variance": 0.008715, "average": 0.971564, "min": 0.470379}, "location": {"width": 445, "top": 730, "height": 17, "left": 111}, "words": "恢复到基线SBP有明显的剂量一时间依赖关系。此方面关于DBP的数据不一致"}, {"probability": {"variance": 0.011054, "average": 0.969808, "min": 0.424105}, "location": {"width": 432, "top": 764, "height": 16, "left": 84}, "words": "地平、阿替洛尔、依那普利、双氢氯噻嗪、氯沙坦和赖诺普利的比较)"}, {"probability": {"variance": 7.2e-05, "average": 0.995958, "min": 0.955487}, "location": {"width": 506, "top": 780, "height": 16, "left": 112}, "words": "替米沙坦治疗如突然中断,数天后血压逐渐恢复到治疗前水平,不出现反跳性高血压"}, {"probability": {"variance": 1.9e-05, "average": 0.998241, "min": 0.973895}, "location": {"width": 754, "top": 796, "height": 17, "left": 112}, "words": "在直接比较两种抗高血压药物的临床实验研究中,替米沙坦治疗组的患者干咳发生率显著低于血管紧张素转换酶抑制剂治疗组"}, {"probability": {"variance": 0.00017, "average": 0.996281, "min": 0.927873}, "location": {"width": 396, "top": 814, "height": 16, "left": 112}, "words": "替米沙坦对于改善死亡率和心血管疾病患病率的作用目前尚未可知"}, {"probability": {"variance": 0, "average": 0.999368, "min": 0.999089}, "location": {"width": 42, "top": 832, "height": 15, "left": 85}, "words": "毒理学"}, {"probability": {"variance": 0.000527, "average": 0.993, "min": 0.879586}, "location": {"width": 412, "top": 880, "height": 16, "left": 85}, "words": "剂和血管紧张素Ⅱ拮抗剂共有的反应,可以使用口服盐类补充剂预防"}, {"probability": {"variance": 0.003799, "average": 0.981924, "min": 0.645709}, "location": {"width": 999, "top": 896, "height": 17, "left": 112}, "words": "在上述两个种属都可见血浆肾素活性增高与肾小球近球细胞肥厚/增生。上述变化,亦是血管紧张素转换酶抑制剂和其它血管紧张素Ⅱ拮抗剂共有的反应,无临床特异性"}, {"probability": {"variance": 3.1e-05, "average": 0.997068, "min": 0.971337}, "location": {"width": 630, "top": 913, "height": 17, "left": 112}, "words": "动物实验显示,替米沙坦对于胎仔产后发育有些潜在的不良影响,包括体重减轻,睁眼延迟,死亡率增高"}, {"probability": {"variance": 0.000176, "average": 0.996313, "min": 0.921403}, "location": {"width": 477, "top": 930, "height": 17, "left": 113}, "words": "体外实验未发现致突变性和相关的诱变活性,在小鼠和大鼠实验中未发现致癌性"}, {"probability": {"variance": 0, "average": 0.999509, "min": 0.999025}, "location": {"width": 88, "top": 947, "height": 16, "left": 82}, "words": "【药代动力学"}, {"probability": {"variance": 1e-06, "average": 0.9985, "min": 0.997283}, "location": {"width": 27, "top": 965, "height": 14, "left": 85}, "words": "吸收"}, {"probability": {"variance": 0.001498, "average": 0.991209, "min": 0.760683}, "location": {"width": 508, "top": 997, "height": 16, "left": 84}, "words": "和饮食状态下服用替米沙坦3小时后血浆浓度近似。AUC的轻度降低不会引起疗效降低"}, {"probability": {"variance": 0.004376, "average": 0.984411, "min": 0.569579}, "location": {"width": 500, "top": 1013, "height": 17, "left": 112}, "words": "剂量和血浆水平无线性关系。在40mg以上剂量时出现Cmax与AUC轻度的不成比例增高"}, {"probability": {"variance": 0.003129, "average": 0.981333, "min": 0.689293}, "location": {"width": 430, "top": 1030, "height": 16, "left": 112}, "words": "性别不同,血浆浓度不同。女性与男性相比Cmx与AUC分别高出近2~3倍"}, {"probability": {"variance": 0.006453, "average": 0.962538, "min": 0.612425}, "location": {"width": 751, "top": 1046, "height": 17, "left": 84}, "words": "分布:替米沙坦大部分与血浆蛋白结合(>995%),主要是白蛋白与a-1酸糖蛋白平均稳态表观分布容积(Vs)约为500L"}, {"probability": {"variance": 0.00524, "average": 0.985498, "min": 0.570272}, "location": {"width": 463, "top": 1063, "height": 17, "left": 84}, "words": "代谢:替米沙坦通过母体化合物与葡糖苷酸结合代谢。结合产物无药理学活性"}, {"probability": {"variance": 1.1e-05, "average": 0.996582, "min": 0.993296}, "location": {"width": 28, "top": 1081, "height": 15, "left": 84}, "words": "消除"}, {"probability": {"variance": 0.000552, "average": 0.992904, "min": 0.847843}, "location": {"width": 587, "top": 1113, "height": 16, "left": 83}, "words": "以推荐剂量服用时,未见临床相关的替米沙坦蓄积作用。血浆浓度女性高于男性,但对疗效无影响"}, {"probability": {"variance": 8e-05, "average": 0.994096, "min": 0.978616}, "location": {"width": 55, "top": 1148, "height": 15, "left": 85}, "words": "相比较高"}, {"probability": {"variance": 3e-06, "average": 0.998414, "min": 0.994562}, "location": {"width": 324, "top": 1164, "height": 16, "left": 86}, "words": "老年人替米沙坦药代动力学在老年人和年轻人无差别"}, {"probability": {"variance": 0.006004, "average": 0.965869, "min": 0.776117}, "location": {"width": 96, "top": 1180, "height": 16, "left": 85}, "words": "肾功能不全患者"}, {"probability": {"variance": 0.000203, "average": 0.994414, "min": 0.894423}, "location": {"width": 877, "top": 1196, "height": 16, "left": 113}, "words": "进行透析的肾功能不全患者血浆浓度较低。替米沙坦在肾功能不全患者与血浆蛋白高度结合,透析不能清除。肾功能不全患者替米沙坦半衰期不变"}, {"probability": {"variance": 0.002031, "average": 0.991463, "min": 0.665315}, "location": {"width": 723, "top": 1213, "height": 17, "left": 84}, "words": "肝功能不全患者药代动力学研究显示肝功能不全患者绝对生物利用度增加约为100%。清除半衰期在肝功能不全患者不变"}, {"probability": {"variance": 0.013414, "average": 0.965721, "min": 0.54834}, "location": {"width": 225, "top": 1230, "height": 16, "left": 83}, "words": "【贮藏】遮光,密封干燥处保存"}, {"probability": {"variance": 0.003998, "average": 0.977584, "min": 0.640758}, "location": {"width": 466, "top": 1245, "height": 18, "left": 83}, "words": "【包装】铝塑泡罩包装,7片×1板/盒,10片×1板/盒,14片×1板/盒"}, {"probability": {"variance": 9e-06, "average": 0.997564, "min": 0.990131}, "location": {"width": 124, "top": 1262, "height": 18, "left": 83}, "words": "【有效期】24个月"}, {"probability": {"variance": 4.4e-05, "average": 0.996285, "min": 0.978141}, "location": {"width": 308, "top": 1246, "height": 29, "left": 858}, "words": "浙江京新药业股份有限公司"}, {"probability": {"variance": 0.010231, "average": 0.943322, "min": 0.606687}, "location": {"width": 189, "top": 1280, "height": 15, "left": 93}, "words": "执行标准】WS1-(x-081)-20112"}, {"probability": {"variance": 0.024478, "average": 0.82817, "min": 0.527525}, "location": {"width": 288, "top": 1274, "height": 15, "left": 856}, "words": " ZHEIANG JINGXIN PHARMACEUTICAL CO LTD"}, {"probability": {"variance": 6.6e-05, "average": 0.996083, "min": 0.963739}, "location": {"width": 196, "top": 1297, "height": 16, "left": 93}, "words": "批准文号】国药准字H20052643"}, {"probability": {"variance": 0.000321, "average": 0.99158, "min": 0.928096}, "location": {"width": 308, "top": 1293, "height": 16, "left": 856}, "words": "生产地址:浙江省新昌县羽林街道新昌大道东路800号"}, {"probability": {"variance": 4e-06, "average": 0.998189, "min": 0.994479}, "location": {"width": 76, "top": 1313, "height": 16, "left": 84}, "words": "【生产企业】"}, {"probability": {"variance": 0.000744, "average": 0.982773, "min": 0.922268}, "location": {"width": 207, "top": 1277, "height": 49, "left": 546}, "words": "0059112"}, {"probability": {"variance": 0.001704, "average": 0.98427, "min": 0.854075}, "location": {"width": 103, "top": 1309, "height": 14, "left": 857}, "words": "邮政编码:312500"}, {"probability": {"variance": 0.000565, "average": 0.981629, "min": 0.897165}, "location": {"width": 156, "top": 1325, "height": 15, "left": 857}, "words": "销售热线:(0575)86096832"}, {"probability": {"variance": 0.016349, "average": 0.945066, "min": 0.484549}, "location": {"width": 155, "top": 1341, "height": 14, "left": 856}, "words": "投诉电话:(0575)86098209"}, {"probability": {"variance": 0.006956, "average": 0.956224, "min": 0.678346}, "location": {"width": 154, "top": 1356, "height": 15, "left": 856}, "words": "传真号码:(0575)86096898"}, {"probability": {"variance": 0.000342, "average": 0.988422, "min": 0.941408}, "location": {"width": 67, "top": 1371, "height": 15, "left": 86}, "words": "B32020-G"}, {"probability": {"variance": 0.006316, "average": 0.830041, "min": 0.757754}, "location": {"width": 176, "top": 1373, "height": 14, "left": 855}, "words": " http: //ww.jingxinoharm com"}], "language": 3}